The present invention relates to novel Death Domain Containing Receptor-5
(DR5) proteins which are members of the tumor necrosis factor (TNF)
receptor family, and have now been shown to bind TRAIL. In particular,
isolated nucleic acid molecules are provided encoding the human DR5
proteins. DR5 polypeptides are also provided as are vectors, host cells
and recombinant methods for producing the same. The invention further
relates to screening methods for identifying antagonists and antagonists
of DR5 activity.
